<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">11903</article-id><article-id pub-id-type="doi">10.7554/eLife.11903</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>GSK3β regulates AKT-induced central nervous system axon regeneration via an eIF2Bε-dependent, mTORC1-independent pathway</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-43655"><name><surname>Guo</surname><given-names>Xinzheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-6444"><name><surname>Snider</surname><given-names>William D</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-43013"><name><surname>Chen</surname><given-names>Bo</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2768-9007</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Ophthalmology and Visual Science</institution>, <institution>Yale University School of Medicine</institution>, <addr-line><named-content content-type="city">New Haven</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">UNC Neuroscience Center</institution>, <institution>University of North Carolina at Chapel Hill</institution>, <addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Neurobiology</institution>, <institution>Yale University School of Medicine</institution>, <addr-line><named-content content-type="city">New Haven</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sonenberg</surname><given-names>Nahum</given-names></name><role>Reviewing editor</role><aff id="aff4"><institution>McGill University</institution>, <country>Canada</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>b.chen@yale.edu</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>14</day><month>03</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>5</volume><elocation-id>e11903</elocation-id><history><date date-type="received"><day>26</day><month>09</month><year>2015</year></date><date date-type="accepted"><day>26</day><month>02</month><year>2016</year></date></history><permissions><copyright-statement>© 2016, Guo et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Guo et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-11903-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.11903.001</object-id><p>Axons fail to regenerate after central nervous system (CNS) injury. Modulation of the PTEN/mTORC1 pathway in retinal ganglion cells (RGCs) promotes axon regeneration after optic nerve injury. Here, we report that AKT activation, downstream of <italic>Pten</italic> deletion, promotes axon regeneration and RGC survival. We further demonstrate that GSK3β plays an indispensable role in mediating AKT-induced axon regeneration. Deletion or inactivation of GSK3β promotes axon regeneration independently of the mTORC1 pathway, whereas constitutive activation of GSK3β reduces AKT-induced axon regeneration. Importantly, we have identified eIF2Bε as a novel downstream effector of GSK3β in regulating axon regeneration. Inactivation of eIF2Bε reduces both GSK3β and AKT-mediated effects on axon regeneration. Constitutive activation of eIF2Bε is sufficient to promote axon regeneration. Our results reveal a key role of the AKT-GSK3β-eIF2Bε signaling module in regulating axon regeneration in the adult mammalian CNS.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.001">http://dx.doi.org/10.7554/eLife.11903.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.11903.002</object-id><title>eLife digest</title><p>The central nervous system consists of the neurons that make up the brain, retina, and spinal cord. Neurons transmit electrical signals along a cable-like structure called an axon. However, an axon cannot regenerate itself, and so injuries that crush or sever the axons can lead to permanent damage. This happens for two reasons: neurons don’t have the same regenerative ability as other cells, and the environment in the central nervous system restricts cell growth.</p><p>The optic nerve transmits visual information from the eye to the brain. Studies in mice with a damaged optic nerve show that it is possible to regenerate the axons of neurons that lack a protein known as PTEN. These studies revealed one molecular pathway by which eliminating PTEN helps to boost the regrowth of axons.</p><p>Now, Guo et al. identify another independent pathway by which eliminating PTEN helps promote axon regeneration in damaged mouse optic nerves. This pathway starts with a growth-promoting enzyme called AKT, which is turned on in neurons that lack PTEN. Indeed, injecting mice with an active form of this enzyme caused the optic nerve fiber to regrow in mice whose optic nerve had been crushed.</p><p>Further experiments revealed that AKT activates a pathway in which another enzyme called GSK3β acts on a protein called eIF2Bε. A future challenge is to simultaneously manipulate the different signaling pathways that have been linked to axon regrowth to investigate whether this combined approach could help repair damage to the central nervous system.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.002">http://dx.doi.org/10.7554/eLife.11903.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>CNS axon regeneration</kwd><kwd>axon injury</kwd><kwd>signal transduction</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005326</institution-id><institution>Yale University</institution></institution-wrap></funding-source><award-id>New Faculty Award</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Bo</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001818</institution-id><institution>Research to Prevent Blindness</institution></institution-wrap></funding-source><award-id>Unrestricted fund to the Yale Eye Center</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Bo</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The AKT-GSK3β-eIF2Bε signaling module plays a key role in promoting axon regeneration in the adult mammalian central nervous system.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Axon injury in the adult mammalian central nervous system (CNS) causes irreversible damages and permanent loss of functions due to a diminished intrinsic regenerative capability of the mature CNS neurons as well as an inhibitory extrinsic environment (<xref ref-type="bibr" rid="bib17">Horner and Gage, 2000</xref>; <xref ref-type="bibr" rid="bib48">Yiu and He, 2006</xref>). Reactivation of the intrinsic regenerative capability promotes CNS axon regeneration after injury (<xref ref-type="bibr" rid="bib11">Fischer et al., 2004</xref>; <xref ref-type="bibr" rid="bib13">Gaub et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Liu et al., 2010</xref>; <xref ref-type="bibr" rid="bib32">Moore et al., 2009</xref>; <xref ref-type="bibr" rid="bib33">O'Donovan et al., 2014</xref>; <xref ref-type="bibr" rid="bib35">Park et al., 2008</xref>; <xref ref-type="bibr" rid="bib40">Smith et al., 2009</xref>; <xref ref-type="bibr" rid="bib46">Watkins et al., 2013</xref>). Significantly, deletion of PTEN (phosphatase and tensin homolog) in adult retinal ganglion cells (RGCs) promotes axon regeneration after optic nerve injury (<xref ref-type="bibr" rid="bib35">Park et al., 2008</xref>). Loss of PTEN leads to the accumulation of PIP<sub>3</sub> (phosphatidylinositol-3,4,5-trisphosphate), resulting in the activation of the serine/threonine kinase AKT via PDK1-mediated phosphorylation (<xref ref-type="bibr" rid="bib4">Carnero et al., 2008</xref>; <xref ref-type="bibr" rid="bib30">Luo et al., 2003</xref>). AKT is a critical node in cell signaling downstream of growth factors, cytokines, and other cellular stimuli and regulates a wide spectrum of cellular functions, which include cell survival, growth, proliferation, metabolism, and migration (<xref ref-type="bibr" rid="bib31">Manning and Cantley, 2007</xref>). The role of AKT in CNS axon regeneration remains to be revealed.</p><p>Activation of mTOR complex 1 (mTORC1) plays an important role in mediating <italic>Pten</italic> deletion-induced axon regeneration (<xref ref-type="bibr" rid="bib35">Park et al., 2008</xref>). However, mTORC1-independent pathway(s) may exist to regulate axon regrowth in the <italic>Pten</italic>-deficient neurons because 1) pharmacological inhibition of mTORC1 by rapamycin treatment only partially neutralizes the effects of <italic>Pten</italic> deficiency on axon regeneration (<xref ref-type="bibr" rid="bib35">Park et al., 2008</xref>); 2) genetic ablation of TSC1 (tuberous sclerosis complex 1), a negative regulator of mTORC1, or manipulation of downstream effectors of mTORC1 only partially but not completely recapitulated the axon regeneration effects mediated by <italic>Pten</italic> deletion (<xref ref-type="bibr" rid="bib35">Park et al., 2008</xref>; <xref ref-type="bibr" rid="bib47">Yang et al., 2014</xref>).</p><p>GSK3 (glycogen synthase kinase 3) is a signal transducer of AKT. In mammals, the GSK3 family consists of two members, GSK3α and GSK3β. AKT inactivates the kinase activity of GSK3 through phosphorylation of GSK3α at Ser21 or GSK3β at Ser9 (<xref ref-type="bibr" rid="bib6">Cross et al., 1995</xref>). Studies in the peripheral nervous system (PNS) have generated different results regarding the role of GSK3 in regulating PNS axon regeneration. Using <italic>Gsk3a</italic>-S21A/<italic>Gsk3b</italic>-S9A double knock-in mice, in which GSK3α/GSK3β cannot be inactivated by AKT-mediated phosphorylation, one group did not observe obviously phenotype in sensory axon regeneration (<xref ref-type="bibr" rid="bib49">Zhang et al., 2014</xref>), whereas the other group reported that sustained GSK3 activity markedly facilitated sciatic nerve regeneration (<xref ref-type="bibr" rid="bib15">Gobrecht et al., 2014</xref>). In the CNS, pharmacological inactivation of GSK3 by the administration of lithium, a GSK3 inhibitor, stimulates axon formation and elongation in the presence or absence of inhibitory substrates after spinal cord injury (<xref ref-type="bibr" rid="bib8">Dill et al., 2008</xref>). However, the mechanism of lithium action is not completely clear as many other potential targets including a number of vital enzymes are also inhibited by lithium in an uncompetitive manner (<xref ref-type="bibr" rid="bib38">Phiel and Klein, 2001</xref>). Thus, genetic evidence is needed to examine the role of GSK3 in CNS axon regeneration.</p><p>In the present study using optic nerve crush (ONC) to model CNS axon injury, we delineate the role of GSK3β in regulating AKT-induced axon regeneration. We further identified eIF2Bε (eukaryotic translation initiation factor 2B epsilon subunit), a substrate of GSK3β, as a novel factor to regulate both GSK3β and AKT-mediated effects on axon regeneration.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>AKT activation, downstream of <italic>Pten</italic> deletion, promotes axon regeneration</title><p>AKT activation, indicated by phosphorylation at Ser473 (<xref ref-type="bibr" rid="bib2">Bozulic and Hemmings, 2009</xref>), was readily detectable in RGCs labeled by anti-Tuj1 immunoreactivity in the developing retina and was significantly reduced in adult mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–B</xref>). PTEN negatively regulates the PI3K/AKT signaling pathway. To examine whether the deletion of <italic>Pten</italic> leads to AKT activation, we injected AAV-Cre into the vitreous body of adult <italic>Pten<sup>f/f</sup></italic> mice, resulting in Cre-mediated <italic>Pten</italic> deletion in RGCs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C–D</xref>), (<xref ref-type="bibr" rid="bib35">Park et al., 2008</xref>). Two weeks after viral injection, we detected increased phosphorylation of AKT at Ser473 in RGCs either with or without ONC, in comparison with <italic>Pten<sup>f/f</sup></italic>mice injected with AAV-GFP as a control (<xref ref-type="fig" rid="fig1">Figure 1A–B</xref>). To investigate whether AKT activation is sufficient to promote axon regeneration, we injected AAV-caAKT (a constitutively active form of AKT [<xref ref-type="bibr" rid="bib22">Kohn et al., 1996</xref>]), or AAV-GFP as a control, into the vitreous body of adult wild-type mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E–F</xref>) and performed ONC two weeks after viral injection. Axon regeneration was examined two weeks after ONC using immunohistochemistry for GAP-43 (<xref ref-type="bibr" rid="bib23">Koprivica et al., 2005</xref>; <xref ref-type="bibr" rid="bib25">Leon et al., 2000</xref>). While very few axon fibers extended beyond the crush site in the AAV-GFP injected control, robust axon regeneration was stimulated in the AAV-caAKT injected retina (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Upon AKT activation, many regenerating axon fibers were observed at the proximal region of the crush site. The number of regenerating axons gradually declined over a longer distance from the lesion site (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). To assess the effect of AKT activation on RGC survival, we quantified the number of Tuj1<sup>+</sup> cells using immunohistochemistry on retinal flatmount preparations two weeks after ONC (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). In comparison to 25.7% of RGCs remaining in the AAV-GFP injected control, significantly more RGCs (48.4%) were scored in the AAV-caAKT injected retina (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Our results indicate that <italic>Pten</italic> deletion activates AKT, and AKT activation promotes both axon regeneration and RGC survival after optic nerve injury.<fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.11903.003</object-id><label>Figure 1.</label><caption><title>AKT activation promotes axon regeneration and RGC survival.</title><p>(<bold>A</bold>) Detection of AKT Phosphorylation at Ser473 in <italic>Pten</italic>-deleted RGCs labeled by anti-Tuj1 immunohistochemistry, with or without (un) optic nerve injury. Scale bar, 20 µm. (<bold>B</bold>) Quantification of phospho-AKT immunofluorescence intensity following <italic>Pten</italic> deletion. Data are presented as mean ± s.d., n=4 per group. *p&lt;0.001, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test. (<bold>C</bold>) Confocal images of optic nerve sections showing regenerating axons labeled by anti-GAP43 immunohistochemistry at 2 weeks after optic nerve injury from AAV-GFP or AAV-caAkt injected eyes. *, crush site. Scale bar, 200 µm. (<bold>D</bold>) Quantification of regenerating axons at different distances distal to the lesion site. Data are presented as mean ± s.d., n=5 per group. *p&lt;0.01, <sup>+</sup>p&lt;0.05, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test. (<bold>E</bold>) Confocal images of retinal whole-mounts showing surviving Tuj1<sup>+</sup> RGCs at 2 weeks after optic nerve injury. Scale bar, 50 µm. (<bold>F</bold>) Quantification of RGC survival at 2 weeks after injury, expressed as a percentage of total Tuj1<sup>+</sup> RGCs in the uninjured retina. Data are presented as mean ± s.d., n=5 per group. *p&lt;0.01, Student’s <italic>t</italic> test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.003">http://dx.doi.org/10.7554/eLife.11903.003</ext-link></p></caption><graphic xlink:href="elife-11903-fig1-v1"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.11903.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Developmental analysis of AKT phosphorylation in RGCs.</title><p>(<bold>A</bold>) Confocal images of retinal sections showing phospho-AKT immunoreactivity in Tuj1<sup>+</sup> RGCs at postnatal day 7, 21, and 60. Scale bar, 20 µm. (<bold>B</bold>) Quantification of phospho-AKT immunofluorescence intensity relative to postnatal day 7. Data are presented as mean ± s.d., n=5 per group. *p&lt;0.001, One-way ANOVA with Dunnett's test. (<bold>C</bold>) Confocal images of retinal sections showing PTEN immunoreactivity in Tuj1<sup>+</sup> RGCs from AAV-GFP or AAV-Cre injected <italic>Pten<sup>f/f</sup></italic> eyes, Scale bar, 20 µm. (<bold>D</bold>) Quantification of PTEN immunofluorescence intensity. Data are presented as mean ± s.d., n=3 per group. *p&lt;0.001, Student’s <italic>t</italic> test. (<bold>E</bold>) Confocal images of retinal sections showing double immunolabeling for Tuj1<sup>+</sup> RGCs and AKT from AAV-GFP or AAV-caAkt injected eyes, Scale bar, 20 µm. (<bold>F</bold>) Quantification of AKT immunofluorescence intensity. Data are presented as mean ± s.d., n=3 per group. *p&lt;0.01, Student’s <italic>t</italic> test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.004">http://dx.doi.org/10.7554/eLife.11903.004</ext-link></p></caption><graphic xlink:href="elife-11903-fig1-figsupp1-v1"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.11903.005</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Inhibition of mTORC1 partially reduces AKT-induced axon regeneration.</title><p>(<bold>A</bold>) Confocal images of optic nerve sections showing regenerating axons labeled by anti-GAP43 immunohistochemistry at 2 weeks after injury from AAV-GFP or AAV-caAkt injected eyes treated with vehicle or rapamycin. *, crush site. Scale bar, 200 µm. (<bold>B</bold>) Quantification of regenerating axons at different distances distal to the lesion site. Data are presented as mean ± s.d., n=6 per group. *p&lt;0.01, <sup>+</sup>p&lt;0.05, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test. (<bold>C</bold>) Confocal images of retinal whole-mounts showing surviving Tuj1<sup>+</sup> RGCs at 2 weeks after optic nerve injury. Scale bar, 50 µm. (<bold>D</bold>) Quantification of RGC survival at 2 weeks after injury, expressed as a percentage of total Tuj1<sup>+</sup> RGCs in the uninjured retina. Data are presented as mean ± s.d., n=5 per group. *p&lt;0.001, One-way ANOVA with Dunnett's test. Data from AAV-GFP was used as comparison control.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.005">http://dx.doi.org/10.7554/eLife.11903.005</ext-link></p></caption><graphic xlink:href="elife-11903-fig1-figsupp2-v1"/></fig></fig-group></p></sec><sec id="s2-2"><title>GSK3β inactivation mediates AKT-induced axon regeneration</title><p>The mTORC1 pathway plays an important role in mediating <italic>Pten</italic> deletion-induced axon regeneration. To examine whether blockade of mTORC1 signaling also affects AKT-induced axon regeneration, we administered rapamycin to inhibit mTORC1 in the AAV-caAKT-injected retinas. In comparison with the vehicle treatment as a control, rapamycin treatment partially reduced the number of regenerating axon fibers (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A–B</xref>). The residual regenerative effect could be due to incomplete blockage of mTORC1 signaling by the drug treatment, or additional mTORC1-independent pathway(s) may exist to regulate axon regeneration downstream of AKT. We also assessed RGC survival after rapamycin treatment. AKT-induced RGC survival was largely neutralized by rapamycin treatment (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C–D</xref>).</p><p>Given the prominent role of GSK3 in developmental axon extension (<xref ref-type="bibr" rid="bib50">Zhou et al., 2004</xref>) and implication of GSK3 in the regenerative axon growth in the PNS (<xref ref-type="bibr" rid="bib15">Gobrecht et al., 2014</xref>; <xref ref-type="bibr" rid="bib39">Saijilafu et al., 2013</xref>), we next examined the role of GSK3 in CNS axon regeneration. Phosphorylation of GSK3β at Ser9 results in inactivation of its kinase activity (<xref ref-type="bibr" rid="bib6">Cross et al., 1995</xref>). Phospho-GSK3β level was higher in the developing retina relative to the adult age (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Two weeks after AAV-caAKT injection in adult wild-type mice, we detected increased phosphorylation of GSK3β at Ser9 in RGCs either with or without ONC, in comparison with the AAV-GFP injected retina as a control (<xref ref-type="fig" rid="fig2">Figure 2A–B</xref>). We also examined whether <italic>Pten</italic> deletion also led to GSK3β phosphorylation at Ser9 in RGCs. As expected, increased phosphorylation of GSK3β was observed in <italic>Pten</italic>-deficient RGCs (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Our results indicate that GSK3β is a downstream target of PTEN/AKT signaling in RGCs. To investigate whether GSK3β inactivation mediates AKT-induced axon regeneration and RGC survival, we co-injected AAV-caAKT with AAV-GSK3β S9A, a Ser-to-Ala mutant of GSK3β that cannot be phosphorylated by AKT and therefore is constitutively active (<xref ref-type="bibr" rid="bib10">Eldar-Finkelman et al., 1996</xref>). In comparison with the AAV-caAKT and AAV-GFP co-injection, regenerative axon growth was significantly reduced by AAV-GSK3β S9A co-injection (<xref ref-type="fig" rid="fig2">Figure 2C–D</xref>). However, AKT-induced RGC survival was not affected by the expression of GSK3β S9A (<xref ref-type="fig" rid="fig2">Figure 2E–F</xref>). Our results indicate that AKT phosphorylates and thus inactivates GSK3β, leading to improved axon regeneration, but not RGC survival.<fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.11903.006</object-id><label>Figure 2.</label><caption><title>GSK3β is an essential downstream effector to mediate AKT-induced axon regeneration.</title><p>(<bold>A</bold>) Immunohistochemical detection of GSK3β phosphorylation at Ser9 in retinal sections from AAV-GFP or AAV-caAkt-injected eyes, either with or without optic nerve injury. Scale bar, 20 µm. (<bold>B</bold>) Quantification of phospho-GSK3β immunofluorescence intensity. Data are presented as mean ± s.d., n=4 per group. *p&lt;0.001, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test. (<bold>C</bold>) Confocal images of optic nerve sections showing regenerating axons labeled by anti-GAP43 immunohistochemistry at 2 weeks after optic nerve injury from AAV-caAKT + AAV-GFP or AAV-caAkt + AAV-GSK3β S9A injected eyes. *, crush site. Scale bar, 200 µm. (<bold>D</bold>) Quantification of regenerating axons at different distances distal to the lesion site. Data are presented as mean ± s.d., n=5 per group. *p&lt;0.01, <sup>+</sup>p&lt;0.05, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test. (<bold>E</bold>) Confocal images of retinal whole-mounts showing surviving Tuj1<sup>+</sup> RGCs at 2 weeks after optic nerve injury. Scale bar, 50 µm. (<bold>F</bold>) Quantification of RGC survival at 2 weeks after injury, expressed as a percentage of total Tuj1<sup>+</sup> RGCs in the uninjured retina. Data are presented as mean ± s.d., n=5 per group.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.006">http://dx.doi.org/10.7554/eLife.11903.006</ext-link></p></caption><graphic xlink:href="elife-11903-fig2-v1"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.11903.007</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Developmental analysis of GSK3β phosphorylation in RGCs.</title><p>(<bold>A</bold>) Confocal images of retinal sections showing double immunolabeling for Tuj1<sup>+</sup> RGCs and phospho-GSK3β at postnatal day 7, 21, and 60. Scale bar, 20 µm. (<bold>B</bold>) Quantification of phospho-GSK3β immunofluorescence intensity relative to postnatal day 7. Data are presented as mean ± s.d., n=5 per group. *p&lt;0.001, One-way ANOVA with Dunnett's test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.007">http://dx.doi.org/10.7554/eLife.11903.007</ext-link></p></caption><graphic xlink:href="elife-11903-fig2-figsupp1-v1"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.11903.008</object-id><label>Figure 2—figure supplement 2.</label><caption><title><italic>Pten</italic> deletion results in GSK3β phosphorylation in RGCs.</title><p>(<bold>A</bold>) Detection of GSK3β phosphorylation in RGCs by double immunolabeling for phospho-GSK3β (Ser9) and Tuj1 in retinal sections from <italic>Pten<sup>f/f </sup></italic>mice injected with AAV-GFP or AAV-Cre, with or without optic nerve crush. Scale bar, 20 µm. (<bold>B</bold>) Quantification of phospho-GSK3β immunofluorescence intensity. Data are presented as mean ± s.d., n=4 per group. *p&lt;0.001, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.008">http://dx.doi.org/10.7554/eLife.11903.008</ext-link></p></caption><graphic xlink:href="elife-11903-fig2-figsupp2-v1"/></fig></fig-group></p></sec><sec id="s2-3"><title>Deletion or inactivation of GSK3β is sufficient to promote axon regeneration</title><p>To investigate whether deletion of <italic>Gsk3b</italic> promotes RGC axon regeneration, we injected AAV-Cre, or AAV-GFP as a control, in the adult <italic>Gsk3b<sup>f/f</sup></italic> mice (<xref ref-type="bibr" rid="bib36">Patel et al., 2008</xref>) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), and examined axon regeneration two weeks after ONC. While no obvious regenerating axon fibers were observed in the AAV-GFP injected control, <italic>Gsk3b</italic> deletion resulted in improved axon regeneration (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We next examined the time course of axon regeneration in <italic>Gsk3b</italic>-deficient RGCs after injury (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). At 1 day after ONC, optic nerve fibers terminated at the crush site in <italic>Gsk3b<sup>f/f</sup></italic> mice injected with either AAV-GFP or AAV-Cre. At 3 days after ONC, we observed axon sprouting in the <italic>Gsk3b</italic>-deleted RGCs. At 7 days after ONC, regenerating axon fibers extended beyond the lesion site in <italic>Gsk3b</italic>-deficient RGCs, overcoming the inhibitory environment at the lesion site labeled by immunohistochemistry for chondroitin sulfate proteoglycan (CSPG) and glial fibrillary acidic protein (GFAP). However, deletion of <italic>Gsk3a</italic> did not stimulate the regenerative response of injured axons (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), although AKT activation also increased its phosphorylation at Ser21 (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). To further examine whether elimination of the kinase activity of GSK3β is responsible for <italic>Gsk3b</italic> deletion-induced axon regeneration, we injected AAV-GSK3β K85A, a kinase dead mutant of GSK3β that inhibits endogenous GSK3β in a dominant negative manner (<xref ref-type="bibr" rid="bib9">Dominguez et al., 1995</xref>), into the vitreous body of adult wild-type mice. Two weeks after ONC, we observed many regenerating axon fibers extending beyond the lesion site in the AAV-GSK3β K85A injected mice, a regenerative response slightly weaker in comparison with <italic>Gsk3b</italic> deletion (<xref ref-type="fig" rid="fig3">Figure 3A,C</xref>). We also analyzed neuronal survival two weeks after ONC in the retinas of <italic>Gsk3a</italic> deletion, <italic>Gsk3b</italic> deletion, and AAV-GSK3β K85A injection. None of these manipulations changed the rate of RGC survival (<xref ref-type="fig" rid="fig3">Figure 3B,D</xref>). Our results indicate that the deletion of <italic>Gsk3b</italic>, but not <italic>Gsk3a</italic>, promotes RGC axon regeneration likely through inactivation of the kinase activity of GSK3β.<fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.11903.009</object-id><label>Figure 3.</label><caption><title>Deletion or inactivation of GSK3β promotes axon regeneration.</title><p>(<bold>A</bold>) Confocal images of optic nerve sections showing regenerating axons labeled by anti-GAP43 immunohistochemistry at 2 weeks after optic nerve crush from <italic>Gsk3a<sup>−/−</sup></italic> mice, <italic>Gsk3b<sup>f/f</sup></italic> mice injected with AAV-GFP or AAV-Cre, or AAV-GSK3β K85A injected wild-type mice. *, crush site. Scale bar, 200 µm. (<bold>B</bold>) Confocal images of retinal whole-mounts showing surviving Tuj1<sup>+</sup> RGCs at 2 weeks after optic nerve injury. Scale bar, 50 µm. (<bold>C</bold>) Quantification of regenerating axons at different distances distal to the lesion site. Data are presented as mean ± s.d., n=5 per group. *p&lt;0.01, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test. (<bold>D</bold>) Quantification of RGC survival at 2 weeks after injury, expressed as a percentage of total Tuj1<sup>+</sup> RGCs in the uninjured retina. Data are presented as mean ± s.d., n=5 per group.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.009">http://dx.doi.org/10.7554/eLife.11903.009</ext-link></p></caption><graphic xlink:href="elife-11903-fig3-v1"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.11903.010</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Cre-mediated <italic>Gsk3b</italic> deletion in RGCs.</title><p>(<bold>A</bold>) Confocal images of retinal sections showing double immunolabeling for Tuj1<sup>+</sup> RGCs and GSK3β from AAV-GFP or AAV-Cre-injected <italic>Gsk3b<sup>f/f </sup></italic>eyes, Scale bar, 20 µm. (<bold>B</bold>) Quantification of GSK3β immunofluorescence intensity. Data are presented as mean ± s.d., n=3 per group. *p&lt;0.01, Student’s <italic>t</italic> test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.010">http://dx.doi.org/10.7554/eLife.11903.010</ext-link></p></caption><graphic xlink:href="elife-11903-fig3-figsupp1-v1"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.11903.011</object-id><label>Figure 3—figure supplement 2.</label><caption><title>A time course study of axon regeneration in <italic>Gsk3b</italic>-deleted RGCs.</title><p>(<bold><bold>A</bold>-<bold>C</bold></bold>) Confocal images of optic nerve sections showing regenerating axons labeled by anti-GAP43 immunohistochemistry at 1, 3, or 7 days from <italic>Gsk3b<sup>f/f</sup></italic> mice injected with AAV-GFP or AAV-Cre. *, crush site. Scale bar, 100 µm. (<bold>D</bold>) Quantification of regenerating axons at 7 days after injury from <italic>Gsk3b<sup>f/f </sup></italic>mice injected with AAV-GFP or AAV-Cre at different distances distal to the lesion site. Data are presented as mean ± s.d., n=4 per group. *p&lt;0.01, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test. (<bold>E</bold>) Confocal images of optic nerve sections showing double immunolabeling for GAP43<sup>+</sup> regenerating axons and chondroitin sulfate proteoglycan (CSPG). Scale bar, 20 µm. (<bold>F</bold>) Confocal images of optic nerve sections showing double immunolabeling for GAP43<sup>+</sup> regenerating axons and glial fibrillary acidic protein (GFAP). Scale bar, 20 µm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.011">http://dx.doi.org/10.7554/eLife.11903.011</ext-link></p></caption><graphic xlink:href="elife-11903-fig3-figsupp2-v1"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.11903.012</object-id><label>Figure 3—figure supplement 3.</label><caption><title>AKT activation increases GSK3α phosphorylation.</title><p>(<bold>A</bold>) Immunohistochemical detection of GSK3α phosphorylation at Ser21 in retinal sections from AAV-GFP or AAV-caAkt injected eyes, with or without optic nerve injury. Scale bar, 20 µm. (<bold>B</bold>) Quantification of RGC phospho-GSK3α immunofluorescence intensity. Data are presented as mean ± s.d., n=4 per group. *p&lt;0.001, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.012">http://dx.doi.org/10.7554/eLife.11903.012</ext-link></p></caption><graphic xlink:href="elife-11903-fig3-figsupp3-v1"/></fig></fig-group></p></sec><sec id="s2-4"><title>GSK3β acts independently of mTORC1 to regulate axon regeneration</title><p>Activation of the mTORC1 pathway is a well-established downstream signaling mechanism in <italic>Pten</italic> deletion-induced axon regeneration (<xref ref-type="bibr" rid="bib35">Park et al., 2008</xref>; <xref ref-type="bibr" rid="bib47">Yang et al., 2014</xref>). And our results demonstrate that GSK3β may represent another important signaling pathway downstream of PTEN/AKT to regulate CNS axon regrowth. To distinguish whether <italic>Gsk3b</italic> deletion-induced axon regeneration is through activation of the mTORC1 pathway or through an mTORC1-independent mechanism, we first examined whether mTORC1 signaling is altered by <italic>Gsk3b</italic> deletion using immunohistochemistry for phospho-S6 ribosomal protein (p-S6) to monitor the activity of mTORC1 in RGCs (<xref ref-type="bibr" rid="bib16">Hay and Sonenberg, 2004</xref>; <xref ref-type="bibr" rid="bib35">Park et al., 2008</xref>). While AKT activation significantly increased the mTORC1 activity, evidenced by a higher fluorescence intensity of p-S6 immunoreactivity in RGCs in adult wild-type mice injected with AAV-caAKT compared to the control injection, <italic>Gsk3b</italic> deletion did not perturb the activity of mTORC1 as the immunofluorescence intensity of p-S6 remained at the same low level as the control (<xref ref-type="fig" rid="fig4">Figure 4A–B</xref>). To further assess whether the mTORC1 pathway contributes to the regenerative effects induced by <italic>Gsk3b</italic> deletion, we administered rapamycin to inhibit mTORC1 activity in <italic>Gsk3b</italic>-deleted RGCs. While rapamycin markedly reduced AKT-induced axon regeneration and RGC survival (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>), <italic>Gsk3b</italic> deficiency-induced axon regeneration was not affected by rapamycin treatment, and neither was RGC survival in <italic>Gsk3b</italic>-deleted RGCs (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). However, treatment with the protein synthesis inhibitor anisomycin significantly reduced <italic>Gsk3b</italic> deletion induced axon regeneration (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Our results indicate that GSK3β-mediated effects on axon regeneration require protein synthesis but are achieved through an mTORC1-independent mechanism.<fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.11903.013</object-id><label>Figure 4.</label><caption><title><italic>Gsk3b</italic> deletion does not alter the mTORC1 pathway.</title><p>(<bold>A</bold>) Confocal images of retinal sections showing double immunolabeling for Tuj1<sup>+</sup> RGCs and phospho-S6 from AAV-GFP, AAV-caAkt, or AAV-Cre (<italic>Gsk3b<sup>f/f</sup></italic>)-injected eyes, with or without optic nerve injury. Scale bar, 20 µm. (<bold>B</bold>) Quantification of phospho-S6 immunofluorescence intensity. Data are presented as mean ± s.d., n=4 per group. *p&lt;0.001, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.013">http://dx.doi.org/10.7554/eLife.11903.013</ext-link></p></caption><graphic xlink:href="elife-11903-fig4-v1"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.11903.014</object-id><label>Figure 4—figure supplement 1.</label><caption><title><italic>Gsk3b</italic> deletion-induced axon regeneration is sensitive to protein synthesis inhibition but not to mTORC1 inhibition.</title><p>(<bold>A</bold>) Confocal images of optic nerve sections showing regenerating axons labeled by anti-GAP43 immunohistochemistry at 2 weeks after injury in <italic>Gsk3b<sup>f/f</sup></italic>mice injected with AAV-Cre with vehicle, rapamycin, or anisomycin treatment. *, crush site. Scale bar, 200 µm. (<bold>B</bold>) Quantification of regenerating axons at different distances distal to the lesion site. Data are presented as mean ± s.d., n=6 per group. *p&lt;0.01, <sup>+</sup>p&lt;0.05, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test. (<bold>C</bold>) Confocal images of retinal whole-mounts showing surviving Tuj1<sup>+</sup> RGCs at 2 weeks after optic nerve injury. Scale bar, 50 µm. (<bold>D</bold>) Quantification of RGC survival at 2 weeks after injury, expressed as a percentage of total Tuj1<sup>+</sup> RGCs in the uninjured retina. Data are presented as mean ± s.d., n=5 per group.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.014">http://dx.doi.org/10.7554/eLife.11903.014</ext-link></p></caption><graphic xlink:href="elife-11903-fig4-figsupp1-v1"/></fig></fig-group></p></sec><sec id="s2-5"><title>eIF2Bε is required for GSK3β-mediated effects on axon regeneration</title><p>GSK3β regulates many cellular processes through phosphorylation of its diverse substrates that include transcription factors, cytoskeletal proteins, motor proteins, and proteins involved in the regulation of cell growth (<xref ref-type="bibr" rid="bib28">Liu et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">Saijilafu et al., 2013</xref>; <xref ref-type="bibr" rid="bib43">Sutherland, 2011</xref>). eIF2B (eukaryotic translation initiation factor 2B) is a heteropentameric guanine nucleotide exchange factor that converts eIF2 (eukaryotic translation initiation factor 2) from the inactive GDP–bound form to the active GTP-bound complex, representing a rate-limiting step in protein translation initiation (<xref ref-type="bibr" rid="bib3">Campbell et al., 2005</xref>; <xref ref-type="bibr" rid="bib37">Pavitt, 2005</xref>). eIF2Bε (eIF2B epsilon subunit), the largest catalytic subunit of eIF2B, is inhibited by GSK3β phosphorylation at the Ser535 site, linking regulation of global protein synthesis to GSK3β signaling (<xref ref-type="bibr" rid="bib34">Pap and Cooper, 2002</xref>; <xref ref-type="bibr" rid="bib44">Wang et al., 2001</xref>). Due to the importance of protein synthesis in the regenerative growth of axons, we examined the role of eIF2Bε in optic never regeneration. Phosphorylation of eIF2Bε at Ser535 in RGCs was significantly higher in adult mice in comparison with that in the developing retina (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>), indicating that elF2Bε-controlled protein translation is maintained at a low basal level in adult RGCs. Optic nerve injury alone did not activate eIF2Bε as the phosphorylation of eIF2Bε was detected at similar levels to uninjured retinas after ONC (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). By contrast, phospho-eIF2Bε (Ser535) immunoreactivity was markedly reduced in <italic>Gsk3b</italic>-deleted RGCs in the presence or absence of axon injury (<xref ref-type="fig" rid="fig5">Figure 5A–B</xref>), indicating increased eIF2Bε activity for protein translation. <italic>Gsk3a</italic> deletion did not change eIF2Bε phosphorylation (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>), suggesting that GSK3α may not regulate eIF2Bε activity in RGCs. To determine the role of eIF2Bε in GSK3β-mediated axon regeneration, we inhibited the activity of eIF2Bε in <italic>Gsk3b</italic>-deleted RGCs by co-injection of AAV-eIF2Bε E572A, a dominant negative mutant of eIF2Bε that lacks catalytic activity but is capable of forming heteropentameric eIF2B complex (<xref ref-type="bibr" rid="bib1">Boesen et al., 2004</xref>; <xref ref-type="bibr" rid="bib45">Wang and Proud, 2008</xref>). Two weeks after ONC, the number of regenerating axons was significantly reduced by AAV-eIF2Bε E572A co-injection (<xref ref-type="fig" rid="fig5">Figure 5C–D</xref>). To examine whether protein synthesis is involved in eIF2Bε-regulated axon regeneration, we used Alexa Fluor-conjugated OPP incorporation assay to label newly translated proteins. While the basal level of protein translation in RGCs was suppressed by treatment with the protein synthesis inhibitor anisomycin, <italic>Gsk3b</italic> deletion resulted in a significant increase in OPP-labeled new synthesized proteins, which was largely negated by eIF2Bε E572A treatment (<xref ref-type="fig" rid="fig5">Figure 5E–F</xref>). These results clearly demonstrate that protein synthesis is tightly controlled by GSK3β/eIF2Bε signaling during axon regeneration. However, inhibition of eIF2Bε had no effect on the survival of <italic>Gsk3b</italic>-deleted RGCs (<xref ref-type="fig" rid="fig5">Figure 5G–H</xref>).<fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.11903.015</object-id><label>Figure 5.</label><caption><title>eIF2Bε is required for <italic>Gsk3b</italic> deletion-induced axon regeneration.</title><p>(<bold>A</bold>) Confocal images of retinal sections showing double immunolabeling for Tuj1<sup>+</sup> RGCs and phospho-eIF2Bε from <italic>Gsk3b<sup>f/f</sup></italic>mice injected with AAV-GFP (Control) or AAV-Cre (<italic>Gsk3b<sup>-/-</sup></italic>), with or without optic nerve injury. Scale bar, 20 µm. (<bold>B</bold>) Quantification of phospho-eIF2Bε immunofluorescence intensity. Data are presented as mean ± s.d., n=5 per group. *p&lt;0.001, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test. (<bold>C</bold>) Confocal images of optic nerve sections showing regenerating axons labeled by anti-GAP43 immunohistochemistry at 2 weeks after optic nerve crush from <italic>Gsk3b<sup>f/f</sup></italic>mice injected with AAV-Cre + AAV-GFP or AAV-Cre + AAV-eIF2Bε E572A. *, crush site. Scale bar, 200 µm. (<bold>D</bold>) Quantification of regenerating axons from <italic>Gsk3b<sup>f/f </sup></italic>mice injected with AAV-Cre + AAV-GFP or AAV-Cre + AAV-eIF2Bε E572A at different distances distal to the lesion site. Data are presented as mean ± s.d., n=9 per group. *p&lt;0.01, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test. (<bold>E</bold>) OPP Alexa Fluor 594 protein synthesis assay in retinal whole-mounts from <italic>Gsk3b<sup>f/f </sup></italic>mice injected with AAV-GFP (Control), AAV-Cre (<italic>Gsk3b<sup>-/-</sup></italic>) + AAV-GFP, or AAV-Cre + AAV-eIF2Bε E572A or treated with anisomycin. Scale bar, 25 µm. (<bold>F</bold>) Quantification of OPP fluorescence intensity. Data are presented as mean ± s.d., n=5 per group. *p&lt;0.01, One-way ANOVA with Tukey’s test. (<bold>G</bold>) Confocal images of retinal whole-mounts showing surviving Tuj1<sup>+</sup> RGCs at 2 weeks after optic nerve injury. Scale bar, 50 µm. (<bold>H</bold>) Quantification of RGC survival at 2 weeks after injury, expressed as a percentage of total Tuj1<sup>+</sup> RGCs in the uninjured retina. Data are presented as mean ± s.d., n=5 per group.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.015">http://dx.doi.org/10.7554/eLife.11903.015</ext-link></p></caption><graphic xlink:href="elife-11903-fig5-v1"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.11903.016</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Developmental analysis of eIF2Bε phosphorylation in RGCs.</title><p>(<bold>A</bold>) Confocal images of retinal sections showing double immunolabeling for Tuj1<sup>+</sup> RGCs and phospho-eIF2Bε at postnatal day 7, 21, and 60. Scale bar, 20 µm. (<bold>B</bold>) Quantification of phospho-eIF2Bε immunofluorescence intensity relative to postnatal day 7. Data are presented as mean ± s.d., n=5 per group. *p&lt;0.001, One-way ANOVA with Dunnett's test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.016">http://dx.doi.org/10.7554/eLife.11903.016</ext-link></p></caption><graphic xlink:href="elife-11903-fig5-figsupp1-v1"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.11903.017</object-id><label>Figure 5—figure supplement 2.</label><caption><title>Analysis of eIF2Bε phosphorylation in <italic>Gsk3a</italic> knockout mice.</title><p>(<bold>A</bold>) Confocal images of retinal sections showing double immunolabeling for Tuj1<sup>+</sup> RGCs and phospho-eIF2Bε in <italic>Gsk3a<sup>-/-</sup></italic> mice or their wild type litter mates as a control, with or without optic nerve injury. Scale bar, 20 µm. (<bold>B</bold>) Quantification of phospho-eIF2Bε immunofluorescence intensity. Data are presented as mean ± s.d., n= 5 per group.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.017">http://dx.doi.org/10.7554/eLife.11903.017</ext-link></p></caption><graphic xlink:href="elife-11903-fig5-figsupp2-v1"/></fig></fig-group></p><p>As AKT is further upstream of eIF2Bε, we next examined the effect of eIF2Bε inhibition on AKT-induced axon regeneration. At 2 weeks after ONC, the regenerative response stimulated by AAV-caAKT injection was significantly reduced by co-injection of AAV-eIF2Bε E572A (<xref ref-type="fig" rid="fig6">Figure 6A–B</xref>), while AKT-induced RGC survival was not perturbed by eIF2Bε E572A inhibition (<xref ref-type="fig" rid="fig6">Figure 6C–D</xref>). Taken together, our results demonstrate that eIF2Bε is required for both AKT and GSK3β-mediated effects on axon regeneration, but plays a minimal role in RGC survival after axon injury.<fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.11903.018</object-id><label>Figure 6.</label><caption><title>eIF2Bε is required for AKT-induced axon regeneration.</title><p>(<bold>A</bold>) Confocal images of optic nerve sections showing regenerating axons labeled by anti-GAP43 immunohistochemistry at 2 weeks after injury from AAV-caAKT + AAV-GFP or AAV-caAkt + AAV-eIF2Bε E572A injected eyes. *, crush site. Scale bar, 200 µm. (<bold>B</bold>) Quantification of regenerating axons from AAV-caAKT + AAV-GFP or AAV-caAkt + AAV-eIF2Bε E572A injected eyes at different distances distal to the lesion site. Data are presented as mean ± s.d., n=5 per group. *p&lt;0.05, <sup>+</sup>p&lt;0.05, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test. (<bold>C</bold>) Confocal images of retinal whole-mounts showing surviving Tuj1<sup>+</sup> RGCs at 2 weeks after optic nerve injury. Scale bar, 50 µm. (<bold>D</bold>) Quantification of RGC survival at 2 weeks after injury, expressed as a percentage of total Tuj1<sup>+</sup> RGCs in the uninjured retina. Data are presented as mean ± s.d., n=5 per group.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.018">http://dx.doi.org/10.7554/eLife.11903.018</ext-link></p></caption><graphic xlink:href="elife-11903-fig6-v1"/></fig></p></sec><sec id="s2-6"><title>Activation of eIF2Bε promotes axon regeneration</title><p>To investigate whether activation of eIF2Bε alone is sufficient to promote axon regeneration, we injected AAV-eIF2Bε S535A, a constitutively active mutant of eIF2Bε that is resistant to GSK3β phosphorylation (<xref ref-type="bibr" rid="bib34">Pap and Cooper, 2002</xref>), in the adult wild-type retina. As expected, expression of eIF2Bε S535A significantly increased protein synthesis in RGCs compared with AAV-GFP injection as a control (<xref ref-type="fig" rid="fig7">Figure 7A–B</xref>). At 2 weeks after ONC, we observed many regenerating axon fibers extending past the crush site in the eIF2Bε S535A treated retinas (<xref ref-type="fig" rid="fig7">Figure 7C–D</xref>). The regenerative effect induced by eIF2Bε activation was reduced by protein synthesis inhibition with anisomycin treatment, but was not affected by mTORC1 inhibition with rapamycin treatment (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>), indicating that mTORC1 signaling plays a minimal role in eIF2Bε-induced axon regeneration. We further assessed whether activation of eIF2Bε affects neuronal survival at 2 weeks after ONC, and found that AAV-eIF2Bε S535A injection did not change the rate of RGC survival in comparison with the control injection (<xref ref-type="fig" rid="fig7">Figure 7E–F</xref>). These results demonstrate that activation of eIF2Bε promotes axon regeneration with minimal effects on RGC survival.<fig-group><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.11903.019</object-id><label>Figure 7.</label><caption><title>eIF2Bε activation promotes axon regeneration.</title><p>(<bold>A</bold>) OPP Alexa Fluor 594 protein synthesis assay in retinal whole-mounts from AAV-GFP or AAV-eIF2Bε S535A injected eyes. Scale bar, 25 µm. (<bold>B</bold>) Quantification of OPP fluorescence intensity. Data are presented as mean ± s.d., n=5 per group. *p&lt;0.01, Student’s <italic>t</italic> test. (<bold>C</bold>) Confocal images of optic nerve sections showing regenerating axons labeled by anti-GAP43 immunohistochemistry at 2 weeks after injury from wild-type mice injected with AAV-GFP or AAV-eIF2Bε S535A. *, crush site. Scale bar, 200 µm. (<bold>D</bold>) Quantification of regenerating axons from retinas injected with AAV-GFP or AAV-eIF2Bε S535A at different distances distal to the lesion site. Data are presented as mean ± s.d., n=5 per group. *p&lt;0.01, <sup>+</sup>p&lt;0.05, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test. (<bold>E</bold>) Confocal images of retinal whole-mounts showing surviving Tuj1<sup>+</sup> RGCs at 2 weeks after optic nerve injury. Scale bar, 50 µm. (<bold>F</bold>) Quantification of RGC survival at 2 weeks after injury, expressed as a percentage of total Tuj1<sup>+</sup> RGCs in the uninjured retina. Data are presented as mean ± s.d., n=5 per group.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.019">http://dx.doi.org/10.7554/eLife.11903.019</ext-link></p></caption><graphic xlink:href="elife-11903-fig7-v1"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.11903.020</object-id><label>Figure 7—figure supplement 1.</label><caption><title>eIF2Bε-induced axon regeneration is sensitive to protein synthesis inhibition but not to mTORC1 inhibition.</title><p>(<bold>A</bold>) Confocal images of optic nerve sections showing regenerating axons labeled by anti-GAP43 immunohistochemistry at 2 weeks after injury from AAV-eIF2Bε S535A injected eyes with vehicle, rapamycin, or anisomycin treatment. *, crush site. Scale bar, 200 µm. (<bold>B</bold>) Quantification of regenerating axons at different distances distal to the lesion site. Data are presented as mean ± s.d., n=5 per group. *p&lt;0.01, Two-way ANOVA with Bonferroni <italic>post hoc</italic> test. (<bold>C</bold>) Confocal images of retinal whole-mounts showing surviving Tuj1<sup>+</sup> RGCs at 2 weeks after optic nerve injury. Scale bar, 50 µm. (<bold>D</bold>) Quantification of RGC survival at 2 weeks after injury, expressed as a percentage of total Tuj1<sup>+</sup> RGCs in the uninjured retina. Data are presented as mean ± s.d., n=5 per group.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.020">http://dx.doi.org/10.7554/eLife.11903.020</ext-link></p></caption><graphic xlink:href="elife-11903-fig7-figsupp1-v1"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.11903.021</object-id><label>Figure 7—figure supplement 2.</label><caption><title>A schematic illustration of GSK3β/eIF2Bε and mTORC1 signaling in AKT-induced CNS axon regeneration.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.11903.021">http://dx.doi.org/10.7554/eLife.11903.021</ext-link></p></caption><graphic xlink:href="elife-11903-fig7-figsupp2-v1"/></fig></fig-group></p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Unlike the PNS neurons that are capable of regenerating axons after nerve injury, neurons in the adult mammalian CNS fail to regenerate axons after nerve damages. Both the inhibitory extrinsic environment and the diminished intrinsic regenerative capability in the adult CNS contribute to the poor regeneration of axons after injury. Removal of the inhibitory influences in the extracellular environment is insufficient to stimulate a major regenerative response. On the other hand, activation of intrinsic signaling pathways within CNS neurons has yielded encouraging results in promoting axon regeneration (<xref ref-type="bibr" rid="bib7">de Lima et al., 2012</xref>; <xref ref-type="bibr" rid="bib24">Kurimoto et al., 2010</xref>; <xref ref-type="bibr" rid="bib27">Liu et al., 2011</xref>; <xref ref-type="bibr" rid="bib35">Park et al., 2008</xref>; <xref ref-type="bibr" rid="bib40">Smith et al., 2009</xref>; <xref ref-type="bibr" rid="bib42">Sun et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Yang et al., 2014</xref>). Deletion of <italic>Pten</italic>, a negative regulator of the PI3K/AKT pathway, stimulated robust axon regeneration (<xref ref-type="bibr" rid="bib35">Park et al., 2008</xref>). We found that AKT was phosphorylated at Ser473 and thus activated in the <italic>Pten</italic>-deleted RGCs. Significantly, expression of a constitutively active myristoylated AKT promoted both axon regeneration and RGC survival. AKT regulates a number of diverging downstream signaling pathways through phosphorylation of diverse cellular targets (<xref ref-type="bibr" rid="bib31">Manning and Cantley, 2007</xref>). Previous studies have established that the mTORC1 pathway is an important downstream signaling in mediating <italic>Pten</italic> deletion-induced axon regeneration, as reactivation of this pathway by TSC1 deletion or S6K1 activation effectively promotes axon regeneration (<xref ref-type="bibr" rid="bib35">Park et al., 2008</xref>; <xref ref-type="bibr" rid="bib47">Yang et al., 2014</xref>). However, mechanisms other than the mTORC1 pathway downstream of <italic>Pten</italic> deletion have not been elucidated.</p><p>Several studies have demonstrated the role of GSK3 signaling in developmental axon growth (<xref ref-type="bibr" rid="bib19">Hur et al., 2011</xref>; <xref ref-type="bibr" rid="bib18">Hur and Zhou, 2010</xref>; <xref ref-type="bibr" rid="bib20">Kim et al., 2006</xref>). In the adult PNS, GSK3 signaling regulates mammalian sensory axon regeneration by inducing the expression of Smad1 (<xref ref-type="bibr" rid="bib39">Saijilafu et al., 2013</xref>). In the spinal cord injury model, neuronal deletion of <italic>Gsk3b</italic> enhances dorsal column axon regeneration via CRMP2-regulated microtubule dynamics, specifically in the growth cone (<xref ref-type="bibr" rid="bib29">Liz et al., 2014</xref>). Here, using the optic nerve injury model, we have demonstrated that GSK3β plays a pivotal role in regulating CNS axon regeneration. <italic>Pten</italic> deletion or AKT activation led to phosphorylation of GSK3β at the site of Ser9, resulting in inactivation of its kinase activity in RGCs. Expression of GSK3β S9A, a kinase active mutant of GSK3β, significantly reduced axon regeneration induced by AKT activation. Deletion of <italic>Gsk3b</italic> or inactivation of GSK3β with the expression of GSK3β K85A, a kinase dead mutant of GSK3β, was sufficient to promote axon regeneration. However, GSK3α did not have these same effects. These results are in line with studies showing GSK3 isoform-specific effects in developmental axon growth (<xref ref-type="bibr" rid="bib5">Chen et al., 2012</xref>). Indeed GSK3α and GSK3β have been shown to act on different substrates in the brain (<xref ref-type="bibr" rid="bib41">Soutar et al., 2010</xref>). We did not assess the results of complete elimination of GSK3 activity, which has been associated with the suppression of axon growth in developmental studies (<xref ref-type="bibr" rid="bib20">Kim et al., 2006</xref>). Interestingly, unlike AKT activation that promoted both axon regeneration and RGC survival, GSK3 inactivation did not promote RGC survival, suggesting that mTORC1 and/or other unidentified factors downstream of AKT are involved in promoting the survival of RGCs.</p><p>How might GSK3β signaling regulate axon regeneration? eIF2Bε, the largest catalytic subunit of eIF2B, plays an important role in initiating protein translation in all eukaryotic cells (<xref ref-type="bibr" rid="bib37">Pavitt, 2005</xref>). The activity of eIF2Bε is inhibited by GSK3β phosphorylation. In response to insulin, GSK3β kinase activity is inhibited, eIF2Bε is dephosphorylated and thus more active, leading to an enhancement of protein translation. In the CNS, eIF2Bε-controlled protein translation is required for the development and maintenance of brain white matter, which is composed of bundles of myelinated axons (<xref ref-type="bibr" rid="bib12">Fogli and Boespflug-Tanguy, 2006</xref>; <xref ref-type="bibr" rid="bib14">Geva et al., 2010</xref>). We found that eIF2Bε is a key downstream target of GSK3β to regulate axon regeneration after optic nerve injury. Inhibition of eIF2Bε with the dominant negative mutant eIF2Bε E572A significantly reduced axon regeneration induced by <italic>Gsk3b</italic> deletion or AKT activation. More importantly, activation of eIF2Bε with the constitutively active mutant eIF2Bε S535A was sufficiently effective to promote axon regeneration, emphasizing the importance of protein synthesis as a major neuronal intrinsic mechanism in CNS axon regeneration.</p><p>Protein synthesis is primarily regulated at the initiation phase, which involves binding of the methionyl–transfer RNA (Met–tRNA<sub>i</sub><sup>Met</sup>) to the small 40s ribosomal subunit to form the 43 s pre-initiation complex, which then binds to an mRNA to form the 48 s pre-initiation complex that scans the AUG start codon. Each of these steps in translation initiation is facilitated by proteins referred to as eukaryotic initiation factors eIFs (<xref ref-type="bibr" rid="bib21">Klann and Dever, 2004</xref>). The tRNA<sub>i</sub><sup>Met</sup> binding to the 40 s ribosomal subunit requires the exchange of GTP-bound for GDP-bound eIF2, which is catalyzed by the guanine-nucleotide exchange factor eIF2B. Therefore, GSK3β-mediated eIF2Bε activation enhances the recycling of eIF2 for further rounds of translational initiation, constituting a critical regulatory mechanism to control the intrinsic regenerative ability of RGCs after nerve injury. The 5’ cap-binding protein eIF4E is required for the binding of the 43 s pre-initiation complex to most eukaryotic mRNAs. mTORC1 activation enhances protein synthesis through phosphorylation of 4E-BP (translation initiation factor 4E-binding protein), a negative regulator of eIF4E. However, 4E-BP inhibition is not sufficient to promote axon regeneration as co-deletion of 4E-BP1/2 in RGCs does not stimulate optic nerve regeneration. Interestingly, activation of S6K1, another downstream factor of mTORC1, promotes RGC axon regeneration (<xref ref-type="bibr" rid="bib47">Yang et al., 2014</xref>). S6K1 activation promotes the translation of 5’ TOP (terminal oligopyrimidine tract) mRNAs, which encode exclusively components of the translation machinery including ribosomal proteins, elongation factors, and poly(A)-binding protein (PABP) (<xref ref-type="bibr" rid="bib16">Hay and Sonenberg, 2004</xref>). It appears that mTORC1 and GSK3β signaling, although acting independently to regulate protein translation downstream of AKT, converge on a common translation regulatory mechanism for axon regeneration.</p><p>In summary, our results provide evidence that the AKT-GSK3β-eIF2Bε signaling module plays a central role in determining the intrinsic axonal growth ability of mature CNS neurons (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>). Identifying various signaling pathways may enable combinatorial treatment to promote axon regeneration after CNS injury.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Animals</title><p>C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, Maine). <italic>Pten<sup>f/f</sup></italic> mice were obtained from Dr. William Cafferty’s laboratory (Yale University, New Haven, USA). <italic>Gsk3a<sup>−/−</sup></italic> and <italic>Gsk3b<sup>f/f</sup></italic> mice were kindly provided by Dr. James R Woodgett (McMaster University, Hamilton, Ontario, Canada). All studies adhered to the procedures consistent with animal protocols approved by the IACUC at Yale University.</p></sec><sec id="s4-2"><title>AAV plasmid vectors and AAV preparation</title><p>pAAV-Cre and pAAV-GFP plasmids were kindly provided by Dr. Kevin Park (University of Miami). For plasmids construction, protein-coding region in pAAV-GFP was replaced by the coding sequence of caAKT (myrAkt delta4-129, Addgene plasmid # 10841, Cambridge, MA), GSK3β S9A (obtained from Dr. Marc B Hershenson, University of Michigan), GSK3β K85A (Addgene plasmid # 14755), eIF2Bε S535A (obtained from Dr. Geoffrey M Cooper, Boston University) and eIF2Bε E572A. pAAV2-RC (Stratagene, La Jolla, CA) and the Helper plasmid were used for co-transfection in HEK293T cells. Discontinuous iodixanol gradient ultracentrifugation was used to purify AAV. AAV titers, determined by real-time PCR, were in the range of 1–5 x 10<sup>12</sup> genome copies per milliliter.</p></sec><sec id="s4-3"><title>Intravitreal injection and optic nerve crush</title><p>Mice were anesthetized with a mix of ketamine (100 mg/kg) and xylazine (10 mg/kg) by intraperitoneal injection. For intravitreal injection, the micropipette was inserted just behind the ora serrata, and 1 µl of AAV solution was injected in the vitreous body. Two weeks after viral injection, optic nerve was exposed and crushed intraorbitally with jeweler’s forceps for 5 s approximately 1 mm behind the optic disc. Eye ointment was applied to protect the cornea after surgery.</p></sec><sec id="s4-4"><title>Immunohistochemistry and fluorescence microscopy</title><p>Eyes with the attached optic nerve segment, surgically removed from perfused mice, were post-fixed in 4% PFA. Retinas were dissected out for either whole-mount preparations or cryosections. The optic nerve was separated from the eye and cut longitudinally with a Leica cryostat. Retinal whole-mounts or sections were blocked in the staining buffer containing 5% normal donkey serum and 0.1% Triton X-100 in PBS for 1 hr before incubation with primary antibodies. Primary antibodies used: Tuj1 (Covance, 1:500, Princeton, NJ), PTEN (Cell Signaling Technology, 1:250, Danvers, MA), p-AKT (Cell Signaling Technology, 1:200), AKT (Cell Signaling Technology, 1:250), p-GSK3α (Abcam, 1:250, UK), p-GSK3β (Cell Signaling Technology, 1:400), GSK3b (Cell Signaling Technology, 1:250), p-S6 (Cell Signaling Technology, 1:200), p-eIF2Bε (EMD Millipore, 1:300, Billerica, MA), GAP43 (obtained from Dr. Larry Benowitz, 1:500), CSPG (Sigma, 1:200, St. Louis, MO), and GFAP (Cell Signaling Technology, 1:200). Secondary antibodies used: DyLight Cy3/594/647-conjugated AffiniPure antibodies (Jackson ImmunoResearch, 1:500, West Grove, PA). Confocal images were acquired using a Zeiss LSM 510 EXCITER microscope. Fluorescence channel colors were switched for co-localization studies if necessary. Images were analyzed and organized using ImageJ and Photoshop.</p></sec><sec id="s4-5"><title>Quantification of RGC survival and axon regeneration</title><p>For RGC counting, retinal whole-mounts were immunostained with Tuj1 antibody, and 8–12 fields (321 x 321 µm) were randomly sampled from the peripheral regions of each retina. Regenerating axons was quantified by counting the number of GAP43 positive axons at different distance from the crush site in four sections per nerve, as described previously (<xref ref-type="bibr" rid="bib35">Park et al., 2008</xref>). The cross-sectional width of the nerve was measured at the point at which the counts were taken and was used to calculate the number of axons per millimeter of the width of the nerve. The number of axons per millimeter was then averaged over all sections. Σa<sub>d</sub>, the total number of axons extending distance <italic>d</italic> in a nerve having a radius of <italic>r</italic>, was estimated by summing over all sections having a thickness <italic>t</italic>: Sa<sub>d</sub>= π<italic>r</italic><sup>2</sup> x [average axons/mm]/<italic>t</italic>.</p></sec><sec id="s4-6"><title>Rapamycin and anisomycin administration</title><p>Rapamycin was administered as previously described (<xref ref-type="bibr" rid="bib35">Park et al., 2008</xref>). Rapamycin (LC Laboratories, Woburn, MA) was dissolved at 20 mg/ml in ethanol for stock. Before each administration, rapamycin was diluted in 5% Tween 80, 5% polyethylene glycol 400 (1.0 mg/ml) in PBS. Rapamycin at 6 mg/kg or the vehicle was injected intraperitoneally once every 2 days after AAV injection. Anisomycin (Cayman Chemical, Ann Arbor, MI) was dissolved in DMSO to prepare a stock solution and diluted in PBS before each administration. Anisomycin (30 mg/kg body weight) or vehicle was injected subcutaneously daily after optic nerve crush. To inhibit OPP incorporation, anisomycin (50 μg/ml) was injected intravitreally 1 hr before and together with OPP administration.</p></sec><sec id="s4-7"><title>Protein synthesis analysis and imaging</title><p>For new protein synthesis analysis and imaging, we used Click-iT Plus OPP Alexa Fluor 594 Protein Synthesis Assay Kit (Life Technologies, Carlsbad, CA). In this assay, OPP (O-propargyl-puromycin) is efficiently incorporated into newly translated proteins that can be detected by fluorescently labeled Alexa Fluor dye. One microliter of OPP reagent (200 µM in PBS) was injected into the vitreous body per eye. One hour after injection, eyes were dissected out after perfusion and were post-fixed in 4% PFA for 4 hr. OPP detection was performed according to the manufacturer’s protocol. Retinas were subsequently immunostained with the Tuj1 antibody to label RGCs.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. James R Woodgett (McMaster University, Hamilton, Ontario, Canada) for providing <italic>Gsk3b<sup>f/f</sup> </italic>and <italic>Gsk3a</italic> knockout mice. We thank Dr. Kevin Park (University of Miami) for providing pAAV-Cre and pAAV-GFP plasmids; Dr. Marc B Hershenson (University of Michigan) for providing GSK3β S9A plasmid; Dr. Geoffrey M Cooper (Boston University) for providing eIF2Bε S535A and eIF2Bε plasmids; Dr. Larry Benowitz (Children’s Hospital, Harvard Medical School) for providing GAP43 antibody. This work was supported by an unrestricted grant from Research to Prevent Blindness to Yale University.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>XG, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>WDS, Discussion of the project design and participation in drafting the manuscript</p></fn><fn fn-type="con" id="con3"><p>BC, Conception and design, Analysis and interpretation of data, Drafting or revising the article</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#2013-11389) of Yale University. Yale University has an approved Animal Welfare Assurance (#A3230-01) on file with the NIH office of Laboratory Animal Welfare. All surgery was performed under ketamine anesthesia, and every effort was made to minimize suffering.</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boesen</surname><given-names>T</given-names></name><name><surname>Mohammad</surname><given-names>SS</given-names></name><name><surname>Pavitt</surname><given-names>GD</given-names></name><name><surname>Andersen</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Structure of the Catalytic Fragment of Translation Initiation Factor 2B and Identification of a Critically Important Catalytic Residue</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>10584</fpage><lpage>10592</lpage><pub-id pub-id-type="doi">10.1074/jbc.M311055200</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozulic</surname><given-names>L</given-names></name><name><surname>Hemmings</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>PIKKing on PKB: regulation of PKB activity by phosphorylation</article-title><source>Current Opinion in Cell Biology</source><volume>21</volume><fpage>256</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2009.02.002</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>SG</given-names></name><name><surname>Hoyle</surname><given-names>NP</given-names></name><name><surname>Ashe</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Dynamic cycling of eIF2 through a large eIF2B-containing cytoplasmic body</article-title><source>The Journal of Cell Biology</source><volume>170</volume><fpage>925</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1083/jcb.200503162</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carnero</surname><given-names>A</given-names></name><name><surname>Blanco-Aparicio</surname><given-names>C</given-names></name><name><surname>Renner</surname><given-names>O</given-names></name><name><surname>Link</surname><given-names>W</given-names></name><name><surname>Leal</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications</article-title><source>Current Cancer Drug Targets</source><volume>8</volume><fpage>187</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.2174/156800908784293659</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Maloney</surname><given-names>JA</given-names></name><name><surname>Kallop</surname><given-names>DY</given-names></name><name><surname>Atwal</surname><given-names>JK</given-names></name><name><surname>Tam</surname><given-names>SJ</given-names></name><name><surname>Baer</surname><given-names>K</given-names></name><name><surname>Kissel</surname><given-names>H</given-names></name><name><surname>Kaminker</surname><given-names>JS</given-names></name><name><surname>Lewcock</surname><given-names>JW</given-names></name><name><surname>Weimer</surname><given-names>RM</given-names></name><name><surname>Watts</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Spatially Coordinated Kinase Signaling Regulates Local Axon Degeneration</article-title><source>Journal of Neuroscience</source><volume>32</volume><fpage>13439</fpage><lpage>13453</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2039-12.2012</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>DAE</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Andjelkovich</surname><given-names>M</given-names></name><name><surname>Hemmings</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B</article-title><source>Nature</source><volume>378</volume><fpage>785</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1038/378785a0</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lima</surname><given-names>S</given-names></name><name><surname>Koriyama</surname><given-names>Y</given-names></name><name><surname>Kurimoto</surname><given-names>T</given-names></name><name><surname>Oliveira</surname><given-names>JT</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Gilbert</surname><given-names>H-Y</given-names></name><name><surname>Fagiolini</surname><given-names>M</given-names></name><name><surname>Martinez</surname><given-names>AMB</given-names></name><name><surname>Benowitz</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Full-length axon regeneration in the adult mouse optic nerve and partial recovery of simple visual behaviors</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>109</volume><fpage>9149</fpage><lpage>9154</lpage><pub-id pub-id-type="doi">10.1073/pnas.1119449109</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dill</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Inactivation of Glycogen Synthase Kinase 3 Promotes Axonal Growth and Recovery in the CNS</article-title><source>Journal of Neuroscience</source><volume>28</volume><fpage>8914</fpage><lpage>8928</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1178-08.2008</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominguez</surname><given-names>I</given-names></name><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Sokol</surname><given-names>SY</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Role of glycogen synthase kinase 3 beta as a negative regulator of dorsoventral axis formation in Xenopus embryos</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>92</volume><fpage>8498</fpage><lpage>8502</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.18.8498</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eldar-Finkelman</surname><given-names>H</given-names></name><name><surname>Argast</surname><given-names>GM</given-names></name><name><surname>Foord</surname><given-names>O</given-names></name><name><surname>Fischer</surname><given-names>EH</given-names></name><name><surname>Krebs</surname><given-names>EG</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>93</volume><fpage>10228</fpage><lpage>10233</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.19.10228</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>D</given-names></name><name><surname>Petkova</surname><given-names>V</given-names></name><name><surname>Thanos</surname><given-names>S</given-names></name><name><surname>Benowitz</surname><given-names>LI</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Switching Mature Retinal Ganglion Cells to a Robust Growth State in Vivo: Gene Expression and Synergy with RhoA Inactivation</article-title><source>Journal of Neuroscience</source><volume>24</volume><fpage>8726</fpage><lpage>8740</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2774-04.2004</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fogli</surname><given-names>A</given-names></name><name><surname>Boespflug-Tanguy</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The large spectrum of eIF2B-related diseases</article-title><source>Biochemical Society Transactions</source><volume>34</volume><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1042/BST0340022</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaub</surname><given-names>P</given-names></name><name><surname>Joshi</surname><given-names>Y</given-names></name><name><surname>Wuttke</surname><given-names>A</given-names></name><name><surname>Naumann</surname><given-names>U</given-names></name><name><surname>Schnichels</surname><given-names>S</given-names></name><name><surname>Heiduschka</surname><given-names>P</given-names></name><name><surname>Di Giovanni</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The histone acetyltransferase p300 promotes intrinsic axonal regeneration</article-title><source>Brain</source><volume>134</volume><fpage>2134</fpage><lpage>2148</lpage><pub-id pub-id-type="doi">10.1093/brain/awr142</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geva</surname><given-names>M</given-names></name><name><surname>Cabilly</surname><given-names>Y</given-names></name><name><surname>Assaf</surname><given-names>Y</given-names></name><name><surname>Mindroul</surname><given-names>N</given-names></name><name><surname>Marom</surname><given-names>L</given-names></name><name><surname>Raini</surname><given-names>G</given-names></name><name><surname>Pinchasi</surname><given-names>D</given-names></name><name><surname>Elroy-Stein</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A mouse model for eukaryotic translation initiation factor 2B-leucodystrophy reveals abnormal development of brain white matter</article-title><source>Brain</source><volume>133</volume><fpage>2448</fpage><lpage>2461</lpage><pub-id pub-id-type="doi">10.1093/brain/awq180</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gobrecht</surname><given-names>P</given-names></name><name><surname>Leibinger</surname><given-names>M</given-names></name><name><surname>Andreadaki</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Sustained GSK3 activity markedly facilitates nerve regeneration</article-title><source>Nature Communications</source><volume>5</volume><pub-id pub-id-type="doi">10.1038/ncomms5561</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>N</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Upstream and downstream of mTOR</article-title><source>Genes &amp; Development</source><volume>18</volume><fpage>1926</fpage><lpage>1945</lpage><pub-id pub-id-type="doi">10.1101/gad.1212704</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horner</surname><given-names>PJ</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Regenerating the damaged central nervous system</article-title><source>Nature</source><volume>407</volume><fpage>963</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1038/35039559</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hur</surname><given-names>E-M</given-names></name><name><surname>Zhou</surname><given-names>F-Q</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>GSK3 signalling in neural development</article-title><source>Nature Reviews Neuroscience</source><volume>11</volume><fpage>539</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1038/nrn2870</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hur</surname><given-names>E-M</given-names></name><name><surname>Saijilafu</surname></name><name><surname>Lee</surname><given-names>BD</given-names></name><name><surname>Kim</surname><given-names>S-J</given-names></name><name><surname>Xu</surname><given-names>W-L</given-names></name><name><surname>Zhou</surname><given-names>F-Q</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>GSK3 controls axon growth via CLASP-mediated regulation of growth cone microtubules</article-title><source>Genes &amp; Development</source><volume>25</volume><fpage>1968</fpage><lpage>1981</lpage><pub-id pub-id-type="doi">10.1101/gad.17015911</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W-Y</given-names></name><name><surname>Zhou</surname><given-names>F-Q</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Yokota</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y-M</given-names></name><name><surname>Yoshimura</surname><given-names>T</given-names></name><name><surname>Kaibuchi</surname><given-names>K</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name><name><surname>Anton</surname><given-names>ES</given-names></name><name><surname>Snider</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Essential Roles for GSK-3s and GSK-3-Primed Substrates in Neurotrophin-Induced and Hippocampal Axon Growth</article-title><source>Neuron</source><volume>52</volume><fpage>981</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2006.10.031</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klann</surname><given-names>E</given-names></name><name><surname>Dever</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Biochemical mechanisms for translational regulation in synaptic plasticity</article-title><source>Nature Reviews Neuroscience</source><volume>5</volume><fpage>931</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1038/nrn1557</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohn</surname><given-names>AD</given-names></name><name><surname>Summers</surname><given-names>SA</given-names></name><name><surname>Birnbaum</surname><given-names>MJ</given-names></name><name><surname>Roth</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Expression of a Constitutively Active Akt Ser/Thr Kinase in 3T3-L1 Adipocytes Stimulates Glucose Uptake and Glucose Transporter 4 Translocation</article-title><source>Journal of Biological Chemistry</source><volume>271</volume><fpage>31372</fpage><lpage>31378</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.49.31372</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koprivica</surname><given-names>V</given-names></name><name><surname>Cho</surname><given-names>KS</given-names></name><name><surname>Park</surname><given-names>JB</given-names></name><name><surname>Yiu</surname><given-names>G</given-names></name><name><surname>Atwal</surname><given-names>J</given-names></name><name><surname>Gore</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Tessier-Lavigne</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>DF</given-names></name><name><surname>He</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>EGFR Activation Mediates Inhibition of Axon Regeneration by Myelin and Chondroitin Sulfate Proteoglycans</article-title><source>Science</source><volume>310</volume><fpage>106</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1126/science.1115462</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurimoto</surname><given-names>T</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Omura</surname><given-names>K</given-names></name><name><surname>Gilbert</surname><given-names>H.-y.</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Cen</surname><given-names>L-P</given-names></name><name><surname>Moko</surname><given-names>L</given-names></name><name><surname>Kugler</surname><given-names>S</given-names></name><name><surname>Benowitz</surname><given-names>LI</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Long-Distance Axon Regeneration in the Mature Optic Nerve: Contributions of Oncomodulin, cAMP, and pten Gene Deletion</article-title><source>Journal of Neuroscience</source><volume>30</volume><fpage>15654</fpage><lpage>15663</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4340-10.2010</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leon</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Nguyen</surname><given-names>J</given-names></name><name><surname>Irwin</surname><given-names>N</given-names></name><name><surname>Benowitz</surname><given-names>LI</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Lens injury stimulates axon regeneration in the mature rat optic nerve</article-title><source>Journal of Neuroscience</source><volume>20</volume><fpage>4615</fpage><lpage>4626</lpage></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Samara</surname><given-names>R</given-names></name><name><surname>Willenberg</surname><given-names>R</given-names></name><name><surname>Sears-Kraxberger</surname><given-names>I</given-names></name><name><surname>Tedeschi</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>KK</given-names></name><name><surname>Jin</surname><given-names>D</given-names></name><name><surname>Cai</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Connolly</surname><given-names>L</given-names></name><name><surname>Steward</surname><given-names>O</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PTEN deletion enhances the regenerative ability of adult corticospinal neurons</article-title><source>Nature Neuroscience</source><volume>13</volume><fpage>1075</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1038/nn.2603</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Tedeschi</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>KK</given-names></name><name><surname>He</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Neuronal Intrinsic Mechanisms of Axon Regeneration</article-title><source>Annual Review of Neuroscience</source><volume>34</volume><fpage>131</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1146/annurev-neuro-061010-113723</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C-M</given-names></name><name><surname>Hur</surname><given-names>E-M</given-names></name><name><surname>Zhou</surname><given-names>F-Q</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Coordinating Gene Expression and Axon Assembly to Control Axon Growth: Potential Role of GSK3 Signaling</article-title><source>Frontiers in Molecular Neuroscience</source><volume>5</volume><pub-id pub-id-type="doi">10.3389/fnmol.2012.00003</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liz</surname><given-names>MA</given-names></name><name><surname>Mar</surname><given-names>FM</given-names></name><name><surname>Santos</surname><given-names>TE</given-names></name><name><surname>Pimentel</surname><given-names>HI</given-names></name><name><surname>Marques</surname><given-names>AM</given-names></name><name><surname>Morgado</surname><given-names>MM</given-names></name><name><surname>Vieira</surname><given-names>S</given-names></name><name><surname>Sousa</surname><given-names>VF</given-names></name><name><surname>Pemble</surname><given-names>H</given-names></name><name><surname>Wittmann</surname><given-names>T</given-names></name><name><surname>Sutherland</surname><given-names>C</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name><name><surname>Sousa</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Neuronal deletion of GSK3β increases microtubule speed in the growth cone and enhances axon regeneration via CRMP-2 and independently of MAP1B and CLASP2</article-title><source>BMC Biology</source><volume>12</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/1741-7007-12-47</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Manning</surname><given-names>BD</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Targeting the PI3K-Akt pathway in human cancer</article-title><source>Cancer Cell</source><volume>4</volume><fpage>257</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/S1535-6108(03)00248-4</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>BD</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>AKT/PKB Signaling: Navigating Downstream</article-title><source>Cell</source><volume>129</volume><fpage>1261</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.06.009</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>DL</given-names></name><name><surname>Blackmore</surname><given-names>MG</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name><name><surname>Bixby</surname><given-names>JL</given-names></name><name><surname>Lemmon</surname><given-names>VP</given-names></name><name><surname>Goldberg</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>KLF Family Members Regulate Intrinsic Axon Regeneration Ability</article-title><source>Science</source><volume>326</volume><fpage>298</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1126/science.1175737</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Donovan</surname><given-names>KJ</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Han</surname><given-names>SB</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>JK</given-names></name><name><surname>Charron</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>H</given-names></name><name><surname>Son</surname><given-names>Y-J</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>B-RAF kinase drives developmental axon growth and promotes axon regeneration in the injured mature CNS</article-title><source>The Journal of Experimental Medicine</source><volume>211</volume><fpage>801</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1084/jem.20131780</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pap</surname><given-names>M</given-names></name><name><surname>Cooper</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Role of Translation Initiation Factor 2B in Control of Cell Survival by the Phosphatidylinositol 3-Kinase/Akt/Glycogen Synthase Kinase 3 Signaling Pathway</article-title><source>Molecular and Cellular Biology</source><volume>22</volume><fpage>578</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1128/MCB.22.2.578-586.2002</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>KK</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Smith</surname><given-names>PD</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Cai</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Connolly</surname><given-names>L</given-names></name><name><surname>Kramvis</surname><given-names>I</given-names></name><name><surname>Sahin</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Promoting Axon Regeneration in the Adult CNS by Modulation of the PTEN/mTOR Pathway</article-title><source>Science</source><volume>322</volume><fpage>963</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1126/science.1161566</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Doble</surname><given-names>BW</given-names></name><name><surname>MacAulay</surname><given-names>K</given-names></name><name><surname>Sinclair</surname><given-names>EM</given-names></name><name><surname>Drucker</surname><given-names>DJ</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Tissue-Specific Role of Glycogen Synthase Kinase 3 in Glucose Homeostasis and Insulin Action</article-title><source>Molecular and Cellular Biology</source><volume>28</volume><fpage>6314</fpage><lpage>6328</lpage><pub-id pub-id-type="doi">10.1128/MCB.00763-08</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavitt</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>eIF2B, a mediator of general and gene-specific translational control</article-title><source>Biochemical Society Transactions</source><volume>33</volume><fpage>1487</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.1042/BST0331487</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phiel</surname><given-names>CJ</given-names></name><name><surname>Klein</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Molecular targets of lithium action</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>41</volume><fpage>789</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.41.1.789</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saijilafu</surname></name><name><surname>Hur</surname><given-names>E-M</given-names></name><name><surname>Liu</surname><given-names>C-M</given-names></name><name><surname>Jiao</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>W-L</given-names></name><name><surname>Zhou</surname><given-names>F-Q</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>PI3K–GSK3 signalling regulates mammalian axon regeneration by inducing the expression of Smad1</article-title><source>Nature Communications</source><volume>4</volume><pub-id pub-id-type="doi">10.1038/ncomms3690</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>PD</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Park</surname><given-names>KK</given-names></name><name><surname>Cai</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Kuwako</surname><given-names>K</given-names></name><name><surname>Martinez-Carrasco</surname><given-names>I</given-names></name><name><surname>Connolly</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>SOCS3 Deletion Promotes Optic Nerve Regeneration in Vivo</article-title><source>Neuron</source><volume>64</volume><fpage>617</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2009.11.021</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soutar</surname><given-names>MPM</given-names></name><name><surname>Kim</surname><given-names>W-Y</given-names></name><name><surname>Williamson</surname><given-names>R</given-names></name><name><surname>Peggie</surname><given-names>M</given-names></name><name><surname>Hastie</surname><given-names>CJ</given-names></name><name><surname>McLauchlan</surname><given-names>H</given-names></name><name><surname>Snider</surname><given-names>WD</given-names></name><name><surname>Gordon-Weeks</surname><given-names>PR</given-names></name><name><surname>Sutherland</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain</article-title><source>Journal of Neurochemistry</source><volume>115</volume><fpage>974</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.06988.x</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Park</surname><given-names>KK</given-names></name><name><surname>Belin</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Yeung</surname><given-names>C</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name><name><surname>Yankner</surname><given-names>BA</given-names></name><name><surname>He</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Sustained axon regeneration induced by co-deletion of PTEN and SOCS3</article-title><source>Nature</source><volume>480</volume><fpage>372</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1038/nature10594</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>What Are the bona fide GSK3 Substrates?</article-title><source>International Journal of Alzheimer's Disease</source><volume>2011</volume><pub-id pub-id-type="doi">10.4061/2011/505607</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Paulin</surname><given-names>FE</given-names></name><name><surname>Campbell</surname><given-names>LE</given-names></name><name><surname>Gomez</surname><given-names>E</given-names></name><name><surname>O'Brien</surname><given-names>K</given-names></name><name><surname>Morrice</surname><given-names>N</given-names></name><name><surname>Proud</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Eukaryotic initiation factor 2B: identification of multiple phosphorylation sites in the epsilon-subunit and their functions in vivo</article-title><source>The EMBO Journal</source><volume>20</volume><fpage>4349</fpage><lpage>4359</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.16.4349</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Proud</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A Novel Mechanism for the Control of Translation Initiation by Amino Acids, Mediated by Phosphorylation of Eukaryotic Initiation Factor 2B</article-title><source>Molecular and Cellular Biology</source><volume>28</volume><fpage>1429</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1128/MCB.01512-07</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname><given-names>TA</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Huntwork-Rodriguez</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Eastham-Anderson</surname><given-names>J</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Kaminker</surname><given-names>JS</given-names></name><name><surname>Tessier-Lavigne</surname><given-names>M</given-names></name><name><surname>Lewcock</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>DLK initiates a transcriptional program that couples apoptotic and regenerative responses to axonal injury</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>110</volume><fpage>4039</fpage><lpage>4044</lpage><pub-id pub-id-type="doi">10.1073/pnas.1211074110</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Miao</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Teng</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Nuriddinov</surname><given-names>J</given-names></name><name><surname>Selzer</surname><given-names>ME</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The mTORC1 effectors S6K1 and 4E-BP play different roles in CNS axon regeneration</article-title><source>Nature Communications</source><volume>5</volume><fpage>5416</fpage><pub-id pub-id-type="doi">10.1038/ncomms6416</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yiu</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Glial inhibition of CNS axon regeneration</article-title><source>Nature Reviews Neuroscience</source><volume>7</volume><fpage>617</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1038/nrn1956</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B-Y</given-names></name><name><surname>Saijilafu</surname></name><name><surname>Liu</surname><given-names>C-M</given-names></name><name><surname>Wang</surname><given-names>R-Y</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Jiao</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>F-Q</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Akt-independent GSK3 inactivation downstream of PI3K signaling regulates mammalian axon regeneration</article-title><source>Biochemical and Biophysical Research Communications</source><volume>443</volume><fpage>743</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2013.12.037</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F-Q</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Dedhar</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Y-H</given-names></name><name><surname>Snider</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>NGF-Induced Axon Growth Is Mediated by Localized Inactivation of GSK-3β and Functions of the Microtubule Plus End Binding Protein APC</article-title><source>Neuron</source><volume>42</volume><fpage>897</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2004.05.011</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.11903.022</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sonenberg</surname><given-names>Nahum</given-names></name><role>Reviewing editor</role><aff id="aff5"><institution>McGill University</institution>, <country>Canada</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your work entitled &quot;GSK3β regulates AKT-induced CNS axon regeneration through an eIF2Bε-dependent, mTORC1-independent signaling pathway&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers: Gary Bassell, Fengquan Zhou and a member of our Board of Reviewing Editors. The evaluation has been overseen by the Reviewing Editor and K VijayRaghavan as the Senior Editor.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>Guo et al. show that the GSK3β-eIF2Bε pathway, downstream of PTEN-AKT, is important for CNS axon regeneration in a model of optic nerve crush (ONC). They demonstrate that upon PTEN genetic ablation (which has been demonstrated to result in CNS axonal outgrowth), there is activation of AKT, downstream phosphorylation and inactivation of GSK3β, and consequently, activation (disinhibition) of eIF2Bε. The activation of this pathway results in significant axon regeneration, accompanied by increased protein synthesis. The identification of the GSK3β-eIF2Bε pathway as relevant for axonal regeneration expands the scope of potential targets to improve axonal regeneration following CNS nerve injury. The study has effectively integrated use of viral vectors to express constitutively active and dominant negative forms of several pathway components, together with Cre-mediated knockout, and systematically show that regeneration is induced in a GSK3β independent of mTORC1 signaling. The data are convincing and the manuscript is presented in a logical and straightforward manner. The experiments were carefully designed and executed, and the results are technically sound.</p><p>Essential revisions:</p><p>1) The statistical methods used through the bulk of the paper are inappropriate. Figure. 1B, 1D; <xref ref-type="fig" rid="fig2">Figure 2B, D</xref>; <xref ref-type="fig" rid="fig3">Figure 3B</xref>; <xref ref-type="fig" rid="fig5">Figure 5B, D</xref>; <xref ref-type="fig" rid="fig6">Figure 6B</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>; and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref> need to be analyzed by a 2-way ANOVA with appropriate post-hoc tests. It is inappropriate to use repeated t-tests. In <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref> there are also no asterisks on the graph, although they are indicated in the legend.</p><p>2) The major method of analysis for pathway activation is the scoring of percent positive cells, which can be subjective and highly variable. It would be helpful to show fluorescence intensity measurements for a couple of the manipulations.</p><p>3) The OPP labeling method for protein synthesis is in need of a negative control experiments using anisomycin to block the incorporation (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><p>4) One of the central elements of this report is the emphasis on the independence of the GSK3β-eIF2Bε pathway, downstream of AKT, from activation of mTORC1 in the stimulation of axon outgrowth following injury. In fact, it appears that unlike mTORC1 activation, the GSK3β-eIF2Bε pathway does not affect RGC survival following ONC (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig3">Figure 3D</xref>, <xref ref-type="fig" rid="fig5">Figure 5G</xref>, <xref ref-type="fig" rid="fig6">Figure 6D</xref> and <xref ref-type="fig" rid="fig7">Figure 7E</xref>) while the data are quite convincing to suggest that both branches affect axonal regeneration. When rapamycin is administered (in the presence of a constitutively active AKT), axonal regeneration is almost completely inhibited (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, panels A and B), but the authors claim that this inhibition is partial. Without a direct comparison between the AAV-GFP, AAV-caAKT, and AAV-caAKT+Rapamycin groups (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>) this claim is weak. The same rationale applies to the statement on the effects on RGC survival (presented in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, panel D).</p><p>5) The magnitude of the regenerative effect that is dependent on GSK3β phosphorylation by AKT (<xref ref-type="fig" rid="fig2">Figure 2D</xref>) is comparable to that of rapamycin (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, panels A and B). Nonetheless, when GSK3β is inactivated (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig5">Figure 5</xref>), the regenerative effect appears smaller than that resulting from AKT constitutive activation (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig6">Figure 6</xref>) (although a direct comparison of these effects is missing). It therefore appears important to acknowledge that both branches, although independent, result in the stimulation of mRNA translation initiation, thus converging on a common mechanism for axonal regeneration. One experiment that is lacking is the demonstration that protein synthesis inhibitors block the regenerative effect of the GSK3β-eIF2Bε signaling axis.</p><p>6) Another aspect in this study that was not addressed is whether the GSK3β-eIF2Bε pathway is indeed modulated by ONC or perhaps other models of CNS nerve injury. In this regard, mTORC1 activity, which is developmentally decreased, is reduced by ONC in RGCs (Park et al. 2008); it would be important to show whether this is the case for the AKT-GSK3β-eIF2Bε pathway.</p><p>7) Relevant to comment #4, is the interesting finding that knocking out GSK3α had no promoting effect. Although the authors mentioned briefly in the Discussion that GSK3α might regulate different substrates from GSK3β, there was no experimental evidence provided. For instance, did AKT activation also inactivate GSK3α in RGCs (Will caAKT lead to increased level of GSK3α-S21 phosphorylation)? How did GSK3α knockout affect the phosphorylation of eIF2Bε (Is eIF2Bε phosphorylation reduced in GSK3α knockout mice)? Answers to these questions would greatly improve the study. These experiments could be performed in a short time.</p><p>8) The OPP labeling in <xref ref-type="fig" rid="fig5">Figure 5E</xref> and <xref ref-type="fig" rid="fig7">Figure 7A</xref> need to be quantified.</p><p>9) Some discussion about the difference between eIF2Bε and eIF4E mediated protein synthesis would be helpful.</p><p>10) In terms of the role of GSK3 signaling in PNS axon regeneration, one study (a) showed that GSK3α/β Ser21/9-Ala double knock-in mice had no obvious phenotype in sensory axon regeneration. The finding was different from a later study (b). Both studies need to be cited. In addition, an earlier study (c) has shown that GSK3β knockout could enhance dorsal column axon regeneration in the spinal cord via CRMP2, which should also be cited.</p><p>a) Zhang BY, et al. (2014) AKT-independent GSK3 inactivation downstream of PI3K signaling regulates mammalian axon regeneration. Biochem Biophys Res Commun 443:743-748.b) Gobrecht P, Leibinger M, Andreadaki A, Fischer D (2014) Sustained GSK3 activity markedly facilitates nerve regeneration. Nat Commun 5:4561.c) Liz MA, et al. (2014) Neuronal deletion of GSK3β increases microtubule speed in the growth cone and enhances axon regeneration via CRMP-2 and independently of MAP1B and CLASP2. BMC Biol 12:47.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.11903.023</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>1) The statistical methods used through the bulk of the paper are inappropriate. <xref ref-type="fig" rid="fig1">Figure 1B, D</xref>, <xref ref-type="fig" rid="fig2">Figure 2B, D</xref>, <xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig5">Figure 5B, D</xref>, <xref ref-type="fig" rid="fig6">Figure 6B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref> need to be analyzed by a 2-way ANOVA with appropriate post-hoc tests. It is inappropriate to use repeated t-tests. In <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref> there are also no asterisks on the graph, although they are indicated in the legend.</italic> </p><p>We thank the reviewers for their suggestions to use statistical methods that are more appropriate for the data analysis. Now we have used two-way ANOVA with Bonferroni post hoc test for <xref ref-type="fig" rid="fig1">Figure 1B, D</xref>; <xref ref-type="fig" rid="fig2">Figure 2B, D</xref>; <xref ref-type="fig" rid="fig3">Figure 3B</xref>; <xref ref-type="fig" rid="fig5">Figure 5B; D</xref>; <xref ref-type="fig" rid="fig6">Figure 6B</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>; and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref> in the initial submission, and they correspond to <xref ref-type="fig" rid="fig1">Figure 1B, D</xref>; <xref ref-type="fig" rid="fig2">Figure 2B, D</xref>; <xref ref-type="fig" rid="fig3">Figure 3C</xref>; <xref ref-type="fig" rid="fig5">Figure 5B, D</xref>; <xref ref-type="fig" rid="fig6">Figure 6B</xref>; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2D</xref>; and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref> respectively in the revised manuscript. In addition, asterisks indicating statistical difference have been added to <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref> in the revised manuscript.</p><p><italic>2) The major method of analysis for pathway activation is the scoring of percent positive cells, which can be subjective and highly variable. It would be helpful to show fluorescence intensity measurements for a couple of the manipulations.</italic> </p><p>We agree with the reviewers that scoring the percentage of positively immunostained cells can be subjective and highly variable from one experiment to another. In the revised manuscript, we have used measurements of immunofluorescence intensity for the analysis of pathway activation for phospho-AKT, phospho-GSK3β, phospho-S6, and phospho-eIF2Bε.</p><p><italic>3) The OPP labeling method for protein synthesis is in need of a negative control experiments using anisomycin to block the incorporation (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</italic> </p><p>As advised by the reviewers, we used anisomycin, injected intravitreally 1 hour before and together with OPP administration, to block protein synthesis, and observed a significant decrease in OPP incorporation. The added negative control experiment is shown in <xref ref-type="fig" rid="fig5">Figure 5E</xref> in the revised manuscript.</p><p><italic>4) One of the central elements of this report is the emphasis on the independence of the GSK3β-eIF2Bε pathway, downstream of AKT, from activation of mTORC1 in the stimulation of axon outgrowth following injury. In fact, it appears that unlike mTORC1 activation, the GSK3β-eIF2Bε pathway does not affect RGC survival following ONC (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig3">Figure 3D</xref>, <xref ref-type="fig" rid="fig5">Figure 5G</xref>, <xref ref-type="fig" rid="fig6">Figure 6D</xref> and <xref ref-type="fig" rid="fig7">Figure 7E</xref>) while the data are quite convincing to suggest that both branches affect axonal regeneration. When rapamycin is administered (in the presence of a constitutively active AKT), axonal regeneration is almost completely inhibited (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, panels A and B), but the authors claim that this inhibition is partial. Without a direct comparison between the AAV-GFP, AAV-caAKT, and AAV-caAKT+Rapamycin groups (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>) this claim is weak. The same rationale applies to the statement on the effects on RGC survival (presented in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, panel D).</italic> </p><p>We agree with the reviewers that a direct comparison between the AAV-GFP, AAV-caAKT, and AAV-caAKT+Rapamycin treatment groups is needed to make a convincing conclusion regarding the role of mTORC1 in the AKT-mediated axon regeneration and RGC survival. In the revised manuscript, a direct comparison of these 3 treatment groups has been made to assess axon regeneration (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A-B</xref>) and RGC survival (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C-D</xref>). We found that inhibition of mTORC1 by rapamycin treatment significantly, but not completely, reduced AKT activation-induced axon regeneration. On the other hand, AKT activation-induced RGC survival was almost completely suppressed by rapamycin treatment.</p><p><italic>5) The magnitude of the regenerative effect that is dependent on GSK3β phosphorylation by AKT (<xref ref-type="fig" rid="fig2">Figure 2D</xref>) is comparable to that of rapamycin (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, panels A and B). Nonetheless, when GSK3β is inactivated (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig5">Figure 5</xref>), the regenerative effect appears smaller than that resulting from AKT constitutive activation (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig6">Figure 6</xref>) (although a direct comparison of these effects is missing). It therefore appears important to acknowledge that both branches, although independent, result in the stimulation of mRNA translation initiation, thus converging on a common mechanism for axonal regeneration. One experiment that is lacking is the demonstration that protein synthesis inhibitors block the regenerative effect of the GSK3β-eIF2Bε signaling axis.</italic> </p><p>The reviewers were correct that GSK3β inactivation, either by Cre-mediated deletion or expression of a kinase dead mutant GSK3β K85A, generated a smaller regenerative effect in comparison to AKT constitutive activation, and this is because both mTORC1 and GSK3β-eIF2Bε signaling branches act independently downstream of AKT to stimulate mRNA translation initiation and promote axon regeneration. To demonstrate that protein synthesis is a common regulatory mechanism for axon regeneration, we have performed the experiments suggested by the reviewers to inhibit protein synthesis using anisomycin and assess GSK3β-deletion induced axon regeneration (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A-B</xref>) and elF2Bε activation induced axon regeneration (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A-B</xref>), and found that anisomycin treatment significantly reduced the regenerative effect of the GSK3β-eIF2Bε signaling axis. In addition, we have also assessed the effect of GSK3β inactivation (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C-D</xref>) or eIF2Bε activation (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C-D</xref>) on RGC survival when protein synthesis was inhibited by anisomycin treatment, and found that the GSK3β-eIF2Bε signaling axis did not affect RGC survival.</p><p><italic>6) Another aspect in this study that was not addressed is whether the GSK3β-eIF2Bε pathway is indeed modulated by ONC or perhaps other models of CNS nerve injury. In this regard, mTORC1 activity, which is developmentally decreased, is reduced by ONC in RGCs (Park et al. 2008); it would be important to show whether this is the case for the AKT-GSK3β-eIF2Bε pathway.</italic> </p><p>To assess whether the AKT-GSK3β-eIF2Bε pathway is developmentally regulated, we analyzed the activity of AKT (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>), GSK3β (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), and eIF2Bε (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>) at postnatal day 7, 21, and 60. Indeed, we found that the AKT-GSK3β-eIF2Bε signaling pathway is developmentally regulated such that this pathway was activated in the developing retina at postnatal day 7 and downregulated in the adult age at postnatal day 21 and 60.</p><p>To assess whether the AKT-GSK3β-eIF2Bε pathway is modulated by optic nerve injury, we collect retinas without injury 1or 3 days after ONC. However, we did not observe a significant change in the phosphorylation of AKT (<xref ref-type="fig" rid="fig1">Figure 1A-B</xref>), GSK3β (<xref ref-type="fig" rid="fig2">Figure 2A-B</xref>), or eIF2Bε (<xref ref-type="fig" rid="fig5">Figure 5A-B</xref>) in comparison to uninjured animals.</p><p><italic>7) Relevant to comment #4, is the interesting finding that knocking out GSK3α had no promoting effect. Although the authors mentioned briefly in the Discussion that GSK3α might regulate different substrates from GSK3β, there was no experimental evidence provided. For instance, did AKT activation also inactivate GSK3α in RGCs (Will caAKT lead to increased level of GSK3α-S21 phosphorylation)? How did GSK3α knockout affect the phosphorylation of eIF2Bε (Is eIF2Bε phosphorylation reduced in GSK3α knockout mice)? Answers to these questions would greatly improve the study. These experiments could be performed in a short time.</italic> </p><p>The reviewers raised important questions regarding the role of GSK3α in RGC axon regeneration since knocking out GSK3α had no promoting effect. To address these questions, we analyzed the activity of GSK3α by performing phospho-GSK3α-Ser21 immunohistochemistry following AAV-caAKT injection, using AAV-GFP injection as a control, and found that AKT activation inactivated GSK3α, either with or without optic nerve injury (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). We have also analyzed the phosphorylation of eIF2Bε in the GSK3α knockout mice (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). However, the phospho-eIF2Bε level was not affected by GSK3α deletion. Our results indicate that both GSK3α and GSK3β are phosphorylated and thus inactivated by AKT, but only GSK3β regulates the activity of eIF2Bε. This may explain why no axon regeneration was observed after optic nerve injury in GSK3α knockout mice.</p><p><italic>8) The OPP labeling in <xref ref-type="fig" rid="fig5">Figure 5E</xref> and <xref ref-type="fig" rid="fig7">Figure 7A</xref> need to be quantified.</italic> </p><p>We have quantified the OPP labeling in <xref ref-type="fig" rid="fig5">Figure 5E</xref> and <xref ref-type="fig" rid="fig7">Figure 7A</xref> by measuring the OPP fluorescence intensity. And new figure panels, <xref ref-type="fig" rid="fig5">Figure 5F</xref> and <xref ref-type="fig" rid="fig7">Figure 7B</xref> respectively, have been added to show quantified results of the OPP labeling in the revised manuscript.</p><p><italic>9) Some discussion about the difference between eIF2Bε and eIF4E mediated protein synthesis would be helpful.</italic> </p><p>While both eIF2Bε and eIF4E play an important role in protein translation initiation, they mediate different steps in the assembly of the translation initiation complex. A detailed discussion has been added in the revised manuscript (Discussion, paragraphs three to five), to describe the differential roles of eIF2Bε and eIF4E in mRNA translation, and how their activity is regulated by GSK3β and mTORC1 in the context of axon regeneration.</p><p><italic>10) In terms of the role of GSK3 signaling in PNS axon regeneration, one study (a) showed that GSK3α/</italic>β <italic>Ser21/9-Ala double knock-in mice had no obvious phenotype in sensory axon regeneration. The finding was different from a later study (b). Both studies need to be cited. In addition, an earlier study (c) has shown that GSK3β knockout could enhance dorsal column axon regeneration in the spinal cord via CRMP2, which should also be cited.</italic> </p><p><italic>a) Zhang BY, et al. (2014) AKT-independent GSK3 inactivation downstream of PI3K signaling regulates mammalian axon regeneration. Biochem Biophys Res Commun 443:743-748.b) Gobrecht P, Leibinger M, Andreadaki A, Fischer D (2014) Sustained GSK3 activity markedly facilitates nerve regeneration. Nat Commun 5:4561.c) Liz MA, et al. (2014) Neuronal deletion of GSK3β increases microtubule speed in the growth cone and enhances axon regeneration via CRMP-2 and independently of MAP1B and CLASP2. BMC Biol 12:47.</italic> </p><p>We have noticed the different results regarding the role of GSK3 in PNS axon regeneration using the GSK3α-S21A/GSK3β-S9A double knock-in mice. One group (Gobrecht P, et al. 2014) showed that constitutive activation of GSK3 resulted in markedly increased axon regeneration, while the other group (Zhang BY, et al. 2014) observed no obvious effects in sensory axon regeneration. We have cited the two studies on page 5 in the revised manuscript.</p><p>Using the spinal cord injury model, Liz MA, et al. showed that neuronal deletion of GSK3β enhances dorsal column axon regeneration via CRMP2-regulated microtubule dynamics, specifically in the growth cone. We have cited this paper in the Discussion section.</p></body></sub-article></article>